Alivus Life Sciences Q1 FY27 Investor Presentation Showcases Robust Growth
Alivus Life Sciences reported Q1 FY27 revenue of ₹6,404 million and EBITDA of ₹2,341 million. The non-GPL business grew 26.5% YoY. The company projects 10%-12% revenue growth for FY27 with EBITDA margins of 30%-32%. Capacity expansions are planned through FY29.
The investor presentation provides a detailed update on financial performance and future outlook, which is relevant for investors but does not announce a specific material corporate action.
The company reported strong financial performance, particularly in its non-GPL business, and provided confident future growth projections and strategic investments.
Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) has released its Investor Presentation for Q1 FY27, highlighting positive business performance and future growth strategies.
The company reported revenue of ₹6,404 million and EBITDA of ₹2,341 million, with EBITDA margins at 36.6%. PAT stood at ₹1,601 million, and PAT margins were 25.0%. The non-GPL business demonstrated strong momentum, growing 27.6% QoQ and 26.5% YoY, driven by healthy demand across geographies and new product launches. Gross margins were 60.2%, up 510 bps YoY, and EBITDA margins improved by 650 bps YoY. Free cash flow generation was robust at ₹901 million, leading to cash and cash equivalents of ₹8,802 million as of June 30, 2026.
The GPL business is expected to be flattish for FY27, with a significant decline in Q1FY27, as it historically skews towards the second half of the fiscal year. The company remains confident in achieving revenue growth of 10%-12% in FY27, while sustaining EBITDA margins in the 30%-32% range. Ongoing investments in capacity expansion and pipeline development are supporting future growth.
Segmental performance showed Generic API revenues growing 7.4% YoY, while the CDMO business saw a 3.8% YoY growth. The Non-GPL business continued its strong trajectory. Regulated markets contributed 83% of Q1FY27 revenues. The company has filed 617 DMFs and CEPs across major markets and added 5 synthetic small molecules to its development grid. Manufacturing capacity expansions are underway at Solapur, Ankleshwar, and Dahej, with planned additions expected through FY27E and FY29E.
What to do with a filing like this
Alivus Life Sciences Limited filed this with the NSE as a statutory disclosure, categorised under investor presentation. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alivus Life Sciences Limited. Read the original for the full detail.